RxDoctor Payments Data

William Young, MD

Family Medicine · Spring Hill, FLNPI 1376649202

Payments from drug & device makers

$4,602in general payments, 2019–2025

Across 241 payments — averaging $19.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$781
  • Bayer$700
  • Amarin Pharma, Inc.$423
  • GSK$361
  • Esperion Therapeutics, Inc.$340
  • plus $922 from 13 others

What the payments were for

  • Food & beverage$4,56099%
  • Education$421%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,602 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$139,093
Medicare patients
177
Services billed
3,066

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban76$79,775
XareltoRivaroxaban49$47,866
JanuviaSitagliptin Phosphate35$34,110
Janumet XrSitagliptin Phos/Metformin Hcl22$31,617
FarxigaDapagliflozin Propanediol17$23,615
TradjentaLinagliptin17$22,807
JardianceEmpagliflozin21$18,697
KerendiaFinerenone19$18,418
JanumetSitagliptin Phos/Metformin Hcl12$13,480
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$13,177
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$9,287
Rosuvastatin Calcium578$7,651
Repatha SyringeEvolocumab22$7,451
SymbicortBudesonide/Formoterol Fumarate22$7,021
Candesartan Cilexetil122$6,948

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$149$79,77576 claims
MerckJanuvia, Janumet Xr, Janumet$88$79,20769 claims
Johnson & JohnsonXarelto$124$47,86649 claims
Boehringer IngelheimTradjenta, Jardiance$121$41,50438 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,074$39,92352 claims
GSKTrelegy Ellipta, Breo Ellipta$361$19,67932 claims
BayerKerendia$700$18,41819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Spring Hill

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →